About Mineralization regulator ANKH
Mineralization regulator ANKH (ANKH) is a protein
from Homo sapiens identified by UniProt accession
Q9HCJ1, 492 residues long.
MolForge cross-references it against 0 known binders and
238 disease associations.
Target properties
| Protein name | Mineralization regulator ANKH |
| UniProt accession | Q9HCJ1 |
| Gene | ANKH |
| Organism | Homo sapiens |
| Length | 492 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (238)
Diseases linked to this target (Open Targets).
- chondrocalcinosis 2 · score 0.79
- craniometaphyseal dysplasia · score 0.69
- HbA1c measurement · score 0.57
- type 2 diabetes mellitus · score 0.49
- glaucoma · score 0.46
- intraocular pressure measurement · score 0.45
- diabetes mellitus · score 0.44
- blood phosphate measurement · score 0.44
- open-angle glaucoma · score 0.40
- blood metabolite measurement · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9HCJ1-F1 | alphafold | PREDICTED | 84.46 | — |
Amino-acid sequence (492 residues)
MVKFPALTHY WPLIRFLVPL GITNIAIDFG EQALNRGIAA VKEDAVEMLA SYGLAYSLMK FFTGPMSDFK NVGLVFVNSK RDRTKAVLCM VVAGAIAAVF HTLIAYSDLG YYIINKLHHV DESVGSKTRR AFLYLAAFPF MDAMAWTHAG ILLKHKYSFL VGCASISDVI AQVVFVAILL HSHLECREPL LIPILSLYMG ALVRCTTLCL GYYKNIHDII PDRSGPELGG DATIRKMLSF WWPLALILAT QRISRPIVNL FVSRDLGGSS AATEAVAILT ATYPVGHMPY GWLTEIRAVY PAFDKNNPSN KLVSTSNTVT AAHIKKFTFV CMALSLTLCF VMFWTPNVSE KILIDIIGVD FAFAELCVVP LRIFSFFPVP VTVRAHLTGW LMTLKKTFVL APSSVLRIIV LIASLVVLPY LGVHGATLGV GSLLAGFVGE STMVAIAACY VYRKQKKKME NESATEGEDS AMTDMPPTEE VTDIVEMREE NE
Explore Mineralization regulator ANKH with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets